PharmAla Advances MDMA Research with Shipment to Yale University
PharmAla Completes Successful Delivery of LaNeo™ MDMA to Yale University
PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a pioneering biotechnology company that specializes in the research and manufacture of MDXX class molecules, proudly announces the successful shipment of LaNeo™ MDMA to Yale University. This achievement marks a significant milestone in PharmAla's commitment to advancing clinical research in psychedelics.
Impact of the Shipment
Nick Kadysh, the Founding CEO of PharmAla, expressed his excitement about the shipment, stating, “We’re very pleased to have delivered this shipment to Yale, especially considering the substantial cross-border challenges we faced. We are actively working on obtaining further permits to export to the U.S., and anticipate more developments soon.”
This particular shipment is designated for an open-label trial aimed at examining the effects of MDMA on social cognition in adults suffering from Borderline Personality Disorder. The research is groundbreaking and opens new avenues for understanding the therapeutic potential of MDMA.
Expert Insights on the Trial
Dr. Sarah Fineberg, the Principal Investigator for the trial, expressed gratitude towards the PharmAla team for their commitment to making this delivery a reality. She stated, “We’re thrilled to begin our trial and are keenly looking forward to future developments that stem from this research.”
Collaboration with MAPS
In a notable move towards transparency and collaboration, PharmAla has authorized the Multidisciplinary Association for Psychedelic Studies (MAPS) to publicly post the PharmAla LaNeo MDMA Investigator’s Brochure (IB) on their website. Previously, access to this critical document was limited to researchers collaborating with PharmAla Biotech.
Rick Doblin, the Founder of MAPS, praised PharmAla for this initiative: “PharmAla's commitment to sharing its Investigator’s Brochure, which summarizes the scientific research surrounding MDMA, is a significant gift to researchers worldwide considering MDMA studies. Their proactive approach in providing not only GMP MDMA but also crucial research insights exemplifies a model for the industry.”
Future Directions for PharmAla
By enhancing access to the PharmAla IB, the company hopes to encourage a broader acceptance and utilization of LaNeo™ MDMA in clinical trials and patient applications. PharmAla's IB remains the sole copyrighted entity owned by PharmAla Biotech, with all rights reserved.
Stock Options Issuance
PharmAla has recently issued stock options to select Board Members and Officers. Each option is subject to a vesting schedule where 25% of the total allotment vests every three months. These options will become entirely vested by the one-year mark of the grant date, which was on May 29. The designated exercise price stands at $0.105 per share, subject to adjustments according to market terms.
Upcoming Appearances
In an exciting upcoming event, PharmAla’s CEO, Nicholas Kadysh, will represent the company at the Canadian Security Exchange’s Summit on Responsible Investing. This event is hosted in Kelowna, and Mr. Kadysh is eager to discuss the innovative strides PharmAla is making in the area of psychedelics.
About PharmAla Biotech Holdings Inc.
PharmAla Biotech Holdings Inc. is at the forefront of research and development in the biopharmaceutical sector, specializing in MDXX class molecules including its flagship product, MDMA. Founded with a mission to alleviate the backlog of available, clinical-grade MDMA and enable various clinical trial endeavors, PharmAla is dedicated to providing groundbreaking solutions within the psychedelic landscape. The organization prioritizes cultivation of constructive relationships with regulatory bodies, underscoring its status as a regulatory-first organization.
For additional inquiries, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is LaNeo™ MDMA?
LaNeo™ MDMA is a novel MDXX class molecule developed by PharmAla Biotech, designed for research and therapeutic applications.
Why is the shipment significant?
This shipment to Yale University represents a major step in the use of MDMA in clinical trials for mental health conditions.
Who is involved in the trial?
The trial is overseen by Dr. Sarah Fineberg and involves adults with Borderline Personality Disorder.
What does the PharmAla IB include?
The Investigator’s Brochure summarizes key research on the effects and benefits of MDMA, and it is now accessible through MAPS.
How does PharmAla contribute to psychedelic research?
PharmAla is committed to advancing the understanding of psychedelics through rigorous scientific research and collaboration with regulatory agencies.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
